NEWS
Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™
Aquestive Therapeutics (NASDAQ: AQST) has commented on the FDA's recent approval of the first non-injection-based epinephrine device for treating severe allergic reactions, including anaphylaxis. The company views this as a positive development for patients seeking alternatives to needle-based epinephrine delivery. Aquestive is developing its own product, Anaphylm™ (epinephrine) Sublingual Film, which could potentially become the first oral epinephrine treatment for anaphylaxis.
Aquestive reiterates its timeline for Anaphylm™, expecting to file a New Drug Application (NDA) with the FDA in Q1 2025. The company anticipates a full product launch, if approved, by late 2025 or early 2026. Currently, Aquestive is conducting its final supportive study, the oral allergy syndrome (OAS) challenge, expected to conclude in late Q3 or early Q4 2024.
Aquestive reiterates its timeline for Anaphylm™, expecting to file a New Drug Application (NDA) with the FDA in Q1 2025. The company anticipates a full product launch, if approved, by late 2025 or early 2026. Currently, Aquestive is conducting its final supportive study, the oral allergy syndrome (OAS) challenge, expected to conclude in late Q3 or early Q4 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Lnova : Oh wow big news thank you for sharing